Supernus, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
29.33
+0.58 (2.02%)
Nov 11, 2026, 1:49 PM EST - Market open
Supernus Revenue
Supernus had revenue of $226.77M in the quarter ending September 30, 2026, with 18.05% growth. This brings the company's total for the last twelve months to $865.11M, up 26.93% year-over-year. In the year 2025, Supernus had annual revenue of $718.95M with 8.63% growth. That makes Supernus the 6,346th largest company in the world by revenue and 1,578th in the United States.
Revenue (ttm)
$865.11M
Revenue Growth
+26.93%
P/S Ratio
4.35
Revenue / Employee
$1,639,618
Employees
838
Market Cap
6.09B
Revenue by Geography
- United States 1.05B 85.0%
- Rest of World 186.00M 15.0%
Fiscal year ended Dec 31, 2025 See the full Supernus breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 718.95M | 57.14M | 8.63% |
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
| Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
| Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
| Dec 31, 2018 | 408.90M | 106.66M | 35.29% |
| Dec 31, 2017 | 302.24M | 87.24M | 40.57% |
| Dec 31, 2016 | 215.00M | 67.54M | 45.80% |
| Dec 31, 2015 | 147.47M | 54.79M | 59.12% |
| Dec 31, 2014 | 92.68M | 80.66M | 671.10% |
| Dec 31, 2013 | 12.02M | 10.54M | 712.09% |
| Dec 31, 2012 | 1.48M | 677.00K | 84.31% |
| Dec 31, 2011 | 803.00K | 697.00K | 657.55% |
| Dec 31, 2010 | 106.00K | -37.82M | -99.72% |
| Dec 31, 2009 | 37.93M | 29.04M | 326.65% |
| Dec 31, 2008 | 8.89M | 4.66M | 109.97% |
| Dec 31, 2007 | 4.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 11.11B |
| Dr. Reddy's Laboratories | 3.44B |
| Amneal Pharmaceuticals | 3.20B |
| Hims & Hers Health | 2.87B |
| Alkermes | 1.75B |
| Lantheus Holdings | 1.56B |
| Kiniksa Pharmaceuticals International, | 945.96M |
| Liquidia | 450.91M |
SUPN News
- 1 day ago - Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 2 days ago - Supernus initiated with a Buy at BofA - TheFly
- 2 days ago - Supernus initiated with a Buy at BofA - TheFly
- 7 days ago - Supernus price target raised to $87 from $67 at Cantor Fitzgerald - TheFly
- 7 days ago - Supernus resumed with an Overweight at Piper Sandler - TheFly
- 7 days ago - Supernus price target lowered to $37 from $55 at Stifel - TheFly
- 9 days ago - Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader - GlobeNewsWire
- 12 days ago - Supernus reports Q3 adjusted operating earnings $55.2M vs. $41.9M last year - TheFly